Navidea biopharmaceuticals announces subscriptions of approximately $14.2 million from its rights offering

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) ("navidea" or the "company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the preliminary results of its rights offering which expired at 5:00 p.m. eastern time on august 24, 2022. the company estimates that the rights offering will result in total subscriptions of approximately $14.2 million. navidea expects to receive from the rights offer
NAVB Ratings Summary
NAVB Quant Ranking